Clinical Guideline on Companion Diagostics (CDx) for Marketed Anti-tumor Drugs (draft)
On August 13, 2020, CMDE announced its preparation of Clinical Guideline on Companion Diagostics (CDx) for Marketed Anti-tumor Drugs (draft). Companion Diagostics (CDx) for Marketed Anti-tumor Drugs mentioned in this guideline refers to the declared CDx that are applied by the relevant IVD manufacturers for the anti-tumor drugs when the drugs are on the market. All kinds of opinions are welcome to be filled in the information collection form and submit it to CMDE before September 10, 2020, via email.
